Storytelling is a part of J Freireich’s legacy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

J enjoyed explaining that the letter J in his name appeared in his birth certificate.

Emil J Freireich in 2016.
Photo courtesy of MD Anderson Cancer Center

He had no idea why his mother, an immigrant seamstress at a Chicago sweatshop, put it there, but it was certainly not an abbreviation for an actual name, Jacob, for example.

J’s J was its own thing. No period was to be used.

Great stories beautifully told are a part of J’s legacy. He spoke with reporters and historians, leaving behind more primary source material than your average Joe.

Emil J Freireich died Feb. 1, aged 93, at MD Anderson Cancer Center.

Here are J’s stories in his own words:

  • Freireich’s conversation with Daniel Hayes, a breast cancer expert at the University of Michigan and former president of the American Society of Clinical Oncology, is particularly entertaining.

  • There is also a beautifully annotated, three-session, seven-hour oral history done by MD Anderson.

  • NIH historians, too, sat down with Freireich. The interview appears here.

  • Another fine resource is a book by John Laszlo, “The Cure of Childhood Leukemia: Into the Age of Miracles.” Laszlo, both a participant and a historian of these events, records a lengthy conversation with Freireich and makes it a part of the narrative.

In this issue, we supplement J’s storytelling with an obituary by MD Anderson, and appreciations by Hagop Kantarjian, Moshe Talpaz, and Otis Brawley.

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login